Mitoxantrone (Teva®)

Common name: Mitoxantrone
Brand name: Teva®
 

What is Mitoxantrone?

Mitoxantrone is a chemotherapy drug used to treat advanced prostate cancer by interfering with the growth and reproduction of cancer cells. This therapy is used in combination with corticosteroids, such as prednisone or prednisolone.


How is Mitoxantrone administered?

Mitoxantrone is administered by injection.
 

What are possible side effects of this treatment?

Everyone responds differently to chemotherapy – some experience many side effects while others experience very few. Below are some side effects experienced by those who received mitoxantrone. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.

 
•    Bleeding / bruising
•    Diarrhea
•    Fatigue
•    Hair loss
•    Infection
•    Liver problems
•    Mouth sores
•    Nausea / vomiting
•    Pain, burning, redness, swelling at injection site
 
 

Is Mitoxantrone covered in my province or territory?

Provincial Coverage: Unknown    
    
Last Reviewed: July 2017




Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Université de Sherbrooke Researchers’ Findings Published in Cancer Research

Sherbrooke, November 16, 2017 – Prostate cancer, the most common cancer in men, affects one out of seven Canadian men.
More

12 innovative Canadian prostate cancer researchers set out to make new Discoveries

Toronto, ON – September 28, 2017: 12 forward-thinking Canadian prostate cancer researchers have been rewarded for their innovation with Movember Discovery Grants.
More

Gray Tools '2017 Together We Are Stronger' campaign a success in creating awareness and raising funds for prostate cancer

BRAMPTON, Ontario, Sept 26, 2017 (GLOBE NEWSWIRE) -- Gray Tools Canada Inc, in cooperation with Prostate Cancer Canada, is proud to announce that its “2017 Together We Are Stronger” initiative raised $4,000, which will go directly towards funding valuable research that is needed to improve the way we diagnose, treat, and support men living with the disease.
More


Click here for news archive